| Market Capitalization (Millions $) |
2,413 |
| Shares
Outstanding (Millions) |
242 |
| Employees |
435 |
| Revenues (TTM) (Millions $) |
886 |
| Net Income (TTM) (Millions $) |
-458 |
| Cash Flow (TTM) (Millions $) |
67 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Biocryst Pharmaceuticals Inc.
is a biotechnology company based in Durham, North Carolina that focuses on developing innovative drugs for the treatment of rare diseases.
The company primarily focuses on developing small-molecule drugs designed to target specific enzymes or proteins in the body that are involved in the disease process.
Biocryst's current pipeline includes a diverse range of drug candidates, including orally-administered treatments for hereditary angioedema (HAE), a rare genetic disorder that causes sudden and severe swelling attacks; Alport syndrome, a rare genetic disorder that affects the kidneys and can lead to kidney failure; and non-alcoholic steatohepatitis (NASH), a type of liver disease that is associated with obesity and diabetes.
Their lead candidate is Orladeyo, an oral medication approved by the FDA for the prevention of HAE attacks in adults and adolescents over the age of 12.
Biocryst is also continuing to work on new indications for Orladeyo and is exploring the potential for it to be used in combination with other medications or as a monotherapy.
Another key focus area for Biocryst is developing antiviral drugs.
They have several candidates in their program, including Galidesivir, which has shown promise in treating a number of viral diseases, including influenza, Ebola, and most recently, COVID-19.
Overall, Biocryst Pharmaceuticals Inc.
has a strong track record of developing innovative drugs to treat rare diseases, and their ongoing research and development efforts position them as a leader in the biotechnology industry.
Company Address: 4505 Emperor Blvd., Suite 200 Durham 27703 NC
Company Phone Number: 859-1302 Stock Exchange / Ticker: NASDAQ BCRX
|
1.11% 
96.8 %